Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Frontier Ip Group Plc LSE:FIPP London Ordinary Share GB00B63PS212 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 65.00 13,683 08:00:10
Bid Price Offer Price High Price Low Price Open Price
63.00 67.00 65.00 65.00 65.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.40 4.18 8.76 7.4 33
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:44 O 376 65.00 GBX

Frontier Ip (FIPP) Latest News

More Frontier Ip News
Frontier Ip Investors    Frontier Ip Takeover Rumours

Frontier Ip (FIPP) Discussions and Chat

Frontier Ip Forums and Chat

Date Time Title Posts
13/11/202021:18Frontier IP144
30/7/201122:11Why have they bothered1

Add a New Thread

Frontier Ip (FIPP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Frontier Ip trades in real-time

Frontier Ip (FIPP) Top Chat Posts

DateSubject
05/12/2020
08:20
Frontier Ip Daily Update: Frontier Ip Group Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker FIPP. The last closing price for Frontier Ip was 65p.
Frontier Ip Group Plc has a 4 week average price of 64p and a 12 week average price of 63.50p.
The 1 year high share price is 84p while the 1 year low share price is currently 46p.
There are currently 50,762,406 shares in issue and the average daily traded volume is 25,985 shares. The market capitalisation of Frontier Ip Group Plc is £32,995,563.90.
27/7/2020
14:57
magic: I asked for 6000 pounds of placing shares, got 3000 pounds at 55p. Anyone can register at PrimaryBid. Looks like a return of share price to around pre placement price.
23/6/2020
12:40
acuere: Fine progress being made in The Vaccine Group abounded today - in which FIPP hold 17%. “The overall progress made by TVG during the past year is likely to result in a material valuation uplift in the holding of TVG in the Group's audited results to 30 June 2020.” I think when investors fully digest the value and potential of Fipps holdings it’s difficult not to see the share price trading much neare a £1 in the ear future.
01/4/2020
08:49
the stigologist: ETX were offering to do this a few days ago Government should share any data they have with all UK AI/ML companies not just one Exscientia $1bn+? Mkt Cap ETX e-therapeutics Mkt Cap £27m
17/2/2020
08:32
entropick: FIPP Frontier IP’s Cambridge Raman Imaging Limited secures €140,000 grant to accelerate development of scanning microscope HTTP://twitter.com/entropick/status/1229322696665829376
01/4/2019
20:08
newtothisgame3: #FIPP #Frontier #IP say good results will pave the way for greater growth https://twitter.com/smallcappick/status/1112808373400035328
13/11/2018
16:40
uk2day: lots of late buying above the offer price today!, somethings cooking!!! cant see your 40p support estimate ever being tested opodio!! 80p resistance to be tested more like!!
06/11/2018
20:49
uk2day: Lol, for a moment there I thought someone had some intelligent input on Fipp!
22/9/2018
11:17
uk2day: just what the doctor ordered!!! lol! Frontier IP Group plc Amprologix to develop new antibiotics with Ingenza 20/09/2018 7:01am RNS Non-Regulatory TIDMFIPP Frontier IP Group plc 20 September 2018 RNS Reach AIM: FIPP 20 September 2018 Frontier IP Group Plc ("Frontier IP" or the "Group") New Portfolio Company - Amprologix to develop new antibiotics to help combat antimicrobial resistance in partnership with Ingenza Frontier IP, a specialist in commercialising university intellectual property, today announces it has taken a 10 per cent stake in Amprologix Limited ("the Company"), a spin-out from the University of Plymouth. The company has been established to introduce new antibiotics, helping to tackle antimicrobial resistance, a major threat to human health globally. It will develop and commercialise the work of Dr Mathew Upton, Professor in Medical Microbiology at the University's School of Biomedical Sciences. The first product from the Company is expected to be a cream containing epidermicin, one of the new antibiotics being developed to combat infections caused by antibiotic-resistant bacteria. Epidermicin can rapidly kill harmful bacteria including MRSA (methicillin resistant Staphylococcus aureus), Streptococcus and Enterococcus at very low doses, even if they are resistant to other antibiotics. No new classes of antibiotics have been introduced into clinical use for the past 30 years, and the company is aiming to meet a growing need for new antibiotics as harmful microbes become increasingly drug resistant. It has already secured industry involvement through a partnership with world-leading biotechnology and synthetic biology company Ingenza. The new company is focused on four areas: -- Developing epidermicin for commercial use -- Discovering additional sources for new classes of antibiotics -- Using Artificial Intelligence to improve antibiotic properties, working with Ingenza, IBM and the National Physical Laboratory -- Developing efficient techniques to manufacture antibiotics at scale in partnership with Ingenza In a relevant infection model, a single dose of epidermicin was as effective as six doses of the current standard of care. The antibiotic was initially recovered from a skin bacterium named Staphylococcus epidermidis, but can now be produced in a microbe suitable for industrial scale-up, using synthetic biology methods developed by Ingenza. Professor Upton initially developed the patented technology working closely with UMI3 Ltd at The University of Manchester, which now takes a 13 per cent stake in the new business. The World Health Organisation warned in February this year that "antibiotic resistance is one of the biggest threats to global health, food security, and development today". A UK government review in 2015, chaired by economist Jim O'Neill, estimated that by 2050, the global cost of antibiotic resistance will rise to US$100 trillion and drug resistant infections will cause 10 million deaths a year, eclipsing the current toll from cancer and diabetes combined. The government estimates there are currently 5,000 deaths each year in the UK because antibiotics no longer work for some infections. https://www.gov.uk/government/news/30-million-of-funding-to-tackle-antimicrobial-resistance Neil Crabb, chief executive of Frontier IP, said: "We are delighted to work with Amprologix to commercialise these potentially life-saving antibiotics, and with a leading industrial partner in the area. It is further sign our business model is gaining traction with universities and industry alike." Professor Mathew Upton, chief scientific officer of Amprologix, said: "It is very exciting to form a new company to take forwards our portfolio of novel antimicrobial compounds. Epidermicin, our lead candidate antibiotic, has excellent potential for treating and preventing serious, drug resistant infections. With our current team, the company will be the ideal vehicle to take epidermicin to the clinic." Dr Ian Fotheringham, managing director of Ingenza, said: "This unique partnership fully exploits the synergy of Ingenza's versatile bio-manufacturing technologies and Amprologix's lead in discovering exciting new antimicrobial classes, spearheaded by Dr Upton's innovative research." ENQUIRIES
27/3/2018
21:54
uk2day: Summary from todays results rns! Frontier IP made good progress in pursuing growth and value for shareholders by: · Generating value from our relationships through working on new spin-outs, significant equity holdings and licensing income · Continuing to build a portfolio showing increasing signs of success · Reviewing and extending our pipeline for sources of high-quality intellectual property · Applying commercialisation expertise and leveraging our extensive network to help portfolio companies grow and achieve their business objectives Performance I am pleased to report we enjoyed an encouraging first half of the year across all areas of the business. Our core strategy is showing ever-more positive signs of delivering value and growth for our portfolio partners and shareholders. Fair value in our portfolio increased 19 per cent to £8,020,000 over the previous six months, representing year-on-year growth of 49 per cent. Pre-tax profits increased 67% to £524,000; cash at £1.85 million. Our continued growth was reflected in a highly successful capital markets day, held in Lisbon, Portugal, after the period end. This was attended by more than 70 participants including academics, industry, government, investors and a number of potential spin-out partners. Results Financial assets at fair value through profit and loss at 31 December 2017 increased to £8,020,000 (30 June 2017: £6,751,000; 31 December 2016: £5,396,000). Total revenue over the first half increased by 41% to £1,188,000 (2016: £843,000) reflecting the higher investment revaluations (unrealised) of £1,068,000 (2016: £711,000) while revenue from services decreased marginally to £120,000 (2016: £132,000). The profit before tax increased by 67% to £524,000 (2016: £314,000) reflecting the higher investment revaluations, partially offset by the higher administrative expenses. Administrative expenses increased by 26% to £667,000 (2016: £529,000) primarily reflecting increased staff, salaries and associated costs. Basic earnings per share was 1.17p (2016: 1.02p). Cash balances stood at £1,849,000 as at 31 December 2017 (30 June 2017: £2,329,000; 31 December 2016: £186,000). Net assets per share as at 31 December 2017 were 32.0p (30 June 2017: 30.7p; 31 December 2016: 26.0p).
27/3/2018
21:41
uk2day: Mon, 26th Mar 2018 07:00 RNS Number : 8368I Frontier IP Group plc 26 March 2018 Frontier IP Group plc [26] March 2018 FIPP RNS Reach Frontier IP Group Plc ("Frontier IP" or "the Group") Team Expansion and London Office Frontier IP Group, which specialises in intellectual property commercialisation, is pleased to announce it has appointed a communications professional to the team and is opening a new base in London. The moves provide a foundation for the next phase of the Group's growth. We are delighted to welcome Andrew Johnson, who will have responsibility for communications and investor relations across the Group's activities. Andrew has more than 20 years' journalism experience and is a former Deputy City Editor of the Daily Express. He has also worked for RBS. Andrew will be based in the City of London at our new offices at 18 King William Street, London, EC4N 7BP. I somehow missed this rns yesterday? I love the comment "The moves provide a foundation for the next phase of the Group's growth" a share price rise from 14p-85p in last 5yrs is growth im already over the moon with!, makes one wonder what increase in value and earnings come from the new base opening in London? and Fipp is still off the public radar! lol!
Frontier Ip share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FIPP
Frontier I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201206 01:07:06